[go: up one dir, main page]

BG107865A - Substituted pyridoindoles as serotonin agonists and antagonists - Google Patents

Substituted pyridoindoles as serotonin agonists and antagonists

Info

Publication number
BG107865A
BG107865A BG107865A BG10786503A BG107865A BG 107865 A BG107865 A BG 107865A BG 107865 A BG107865 A BG 107865A BG 10786503 A BG10786503 A BG 10786503A BG 107865 A BG107865 A BG 107865A
Authority
BG
Bulgaria
Prior art keywords
disorders
compounds
antagonists
serotonin agonists
certain
Prior art date
Application number
BG107865A
Other languages
Bulgarian (bg)
English (en)
Inventor
Albert Robichaud
John M. Fevig
Ian S. Mitchell
Taekyu Lee
Wenting Chen
Joseph Cacciola
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BG107865A publication Critical patent/BG107865A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/16Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BG107865A 2000-12-20 2003-05-30 Substituted pyridoindoles as serotonin agonists and antagonists BG107865A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25674000P 2000-12-20 2000-12-20
PCT/US2001/049371 WO2002059129A2 (en) 2000-12-20 2001-12-19 Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists

Publications (1)

Publication Number Publication Date
BG107865A true BG107865A (en) 2004-07-30

Family

ID=22973405

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107865A BG107865A (en) 2000-12-20 2003-05-30 Substituted pyridoindoles as serotonin agonists and antagonists

Country Status (18)

Country Link
US (1) US6699852B2 (no)
EP (1) EP1343791A2 (no)
JP (1) JP4231290B2 (no)
KR (1) KR20030070073A (no)
BG (1) BG107865A (no)
BR (1) BR0116429A (no)
CA (1) CA2432185C (no)
EE (1) EE200300296A (no)
HU (1) HUP0303432A3 (no)
IL (1) IL156354A0 (no)
IS (1) IS6849A (no)
MX (1) MXPA03005438A (no)
NO (1) NO20032797L (no)
PL (1) PL366233A1 (no)
RU (1) RU2003121304A (no)
SK (1) SK7042003A3 (no)
WO (1) WO2002059129A2 (no)
ZA (1) ZA200304305B (no)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031200A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
AR031199A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
AR031202A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
TW200307540A (en) * 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) * 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
IL166593A0 (en) * 2002-08-02 2006-01-15 Racemization and enantiomer separation of clopidogrel
US7109339B2 (en) 2002-12-19 2006-09-19 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
GB0306604D0 (en) * 2003-03-21 2003-04-30 Curidium Ltd Second medical use
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
AU2005222632B2 (en) 2004-03-15 2012-02-09 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
AR052227A1 (es) * 2004-11-05 2007-03-07 Wyeth Corp Metabolitos derivados de [1,4] diazepin [ 6,7,1-ij] quinolina, metodos de preparacion y usos de los mismos
AT502251B1 (de) * 2005-05-06 2007-12-15 Puchegger U Beisteiner Parkett Fussbodenschleifmaschine
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
AU2006275694A1 (en) * 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1H-pyrido(4,3,b)indoles as serotonin receptor agonists and antagonists
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
CL2007000773A1 (es) * 2006-03-24 2008-01-25 Wyeth Corp Uso de compuestos derivados de diazepina condensada para el tratamiento de un desorden cognitivo como add o adhd;o su uso para tratar spm o pmdd.
PE20081192A1 (es) * 2006-03-24 2008-10-07 Wyeth Corp Tratamiento del dolor
MX2008012105A (es) * 2006-03-24 2008-10-03 Wyeth Corp Metodos para modular la funcion de la vejiga.
CN101410112A (zh) * 2006-03-24 2009-04-15 惠氏公司 治疗抑郁症的新治疗组合
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
RU2329044C1 (ru) * 2006-11-16 2008-07-20 Андрей Александрович Иващенко Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
KR101999300B1 (ko) 2007-03-12 2019-07-12 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
BRPI0907122B8 (pt) 2008-01-11 2021-05-25 Albany Molecular Res Inc compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8618299B2 (en) * 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
US8637501B2 (en) 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
US8367655B2 (en) * 2009-07-03 2013-02-05 Daya Drug Discoveries, Inc. Pyridoindolobenzox—and thiazepine derivatives and uses thereof
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
US9556200B2 (en) * 2012-03-06 2017-01-31 Takeda Pharmaceutical Company Limited Tricyclic compound
CA2870303A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Organic compounds
HK1215170A1 (zh) 2012-11-14 2016-08-19 The Johns Hopkins University 治療精神分裂症的方法和組合物
HUE053159T2 (hu) 2013-03-15 2021-06-28 Intra Cellular Therapies Inc Szerves vegyületek
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
IL246002B2 (en) 2013-12-03 2024-11-01 Intra Cellular Therapies Inc Converted compounds of gamma-carboline fused with heterocycles for use in the treatment of residual symptoms of psychosis and a long-acting injectable preparation containing these compounds in a matrix
JP2017509677A (ja) 2014-04-04 2017-04-06 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
IL318649A (en) 2016-01-26 2025-03-01 Intra Cellular Therapies Inc Organic compounds
BR112018069594B1 (pt) 2016-03-25 2023-12-05 Intra-Cellular Therapies, Inc Compostos orgânicos, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou profilaxia de um distúrbio do sistema nervoso central
JP2019513143A (ja) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規塩類および結晶
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California Compounds for increasing neural plasticity
WO2018071233A1 (en) 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
IL304026B2 (en) 2017-03-24 2024-11-01 Intra Cellular Therapies Inc A pharmaceutical preparation containing 1-(4-fluoro-phenyl)-4-((Sa10,Rb6)-3-D2-2,2-methyl-2, 3, a10, 10, 9, b6- hexahydro-H7, H1- Pyrido[3',4',:4,5]pyrrolo[3,2,1-de]quioxalin-8-yl)-butan-1-one and its uses
IL272252B2 (en) 2017-07-26 2024-03-01 Intra Cellular Therapies Inc Derivatives of substituted heterocycle fused gamma-carbolines, pharmaceutical compositions comnprising them and their use in treatment
MX2020000968A (es) 2017-07-26 2020-09-28 Intra Cellular Therapies Inc Compuestos organicos.
CN111107847A (zh) 2017-09-26 2020-05-05 细胞内治疗公司 新的盐和晶体
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
EP3765021A4 (en) 2018-03-16 2022-03-09 Intra-Cellular Therapies, Inc. NOVEL PROCESSES
WO2019183341A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Organic compounds
JP7476115B2 (ja) 2018-06-06 2024-04-30 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規の塩および結晶
MX2020013335A (es) 2018-06-08 2021-05-27 Intra Cellular Therapies Inc Metodos novedosos.
CA3240552A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
MX2021002322A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
BR112021003838A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
US12297200B2 (en) 2018-12-17 2025-05-13 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
US12195462B2 (en) 2018-12-17 2025-01-14 Intra-Cellular Therapies, Inc. Organic compound
IL315005B1 (en) 2018-12-17 2025-12-01 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
EP3897643B1 (en) 2018-12-21 2023-11-15 Intra-Cellular Therapies, Inc. A pyridopyrroloquinoxaline compound and its medical use
EP3897621A4 (en) * 2018-12-21 2022-09-07 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
CN113784962B (zh) 2019-02-27 2025-04-25 加利福尼亚大学董事会 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
MX2022000143A (es) 2019-07-07 2022-02-17 Intra Cellular Therapies Inc Metodos novedosos.
EP4034119A4 (en) 2019-09-25 2023-10-18 Intra-Cellular Therapies, Inc. NOVEL METHODS
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC COMPOUND
JP2025502615A (ja) 2021-12-15 2025-01-28 デリックス セラピューティクス,インク. フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299078A (en) 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US4183936A (en) * 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4238607A (en) * 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4013652A (en) 1972-06-19 1977-03-22 Endo Laboratories, Inc. Pyridopyrrolobenzoxazine
US3914421A (en) * 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
FR2213283A1 (en) 1973-11-15 1974-08-02 Inst Im Ordzhonikidze Pyrazino(1,2,3-ab)beta carbolines and homologues - antidepressants not acting by MAO inhibition
US4088647A (en) 1976-02-04 1978-05-09 Glushkov Robert Georgievich Pyrazino (1,2,3-ab)-β-carboline derivatives and salts thereof and method of preparing same
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
US5328905A (en) 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
EP0300541B1 (en) 1987-07-20 1996-03-27 Duphar International Research B.V 8,9-anellated-1,2,3,4-tetrahydro-beta-carboline derivatives
JPH02180885A (ja) 1988-09-01 1990-07-13 Glaxo Group Ltd ラクタム誘導体
US5223625A (en) 1988-12-22 1993-06-29 Duphar International Research B.V. Annelated indolo [3,2,-C]lactams
CA2011107A1 (en) 1990-02-28 1991-08-31 David E. Bays Lactam derivatives
CA2174543A1 (en) 1993-10-20 1995-04-27 Nobuyuki Yasuda Indole derivative
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
US6407092B1 (en) * 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
IL147108A0 (en) * 1999-06-15 2002-08-14 Du Pont Pharm Co Substituted heterocycle fused gamma-carbolines

Also Published As

Publication number Publication date
CA2432185A1 (en) 2002-08-01
CA2432185C (en) 2011-11-08
PL366233A1 (en) 2005-01-24
HUP0303432A3 (en) 2012-09-28
US20020173503A1 (en) 2002-11-21
BR0116429A (pt) 2006-05-09
IS6849A (is) 2003-06-18
WO2002059129A2 (en) 2002-08-01
KR20030070073A (ko) 2003-08-27
WO2002059129A3 (en) 2003-01-30
EE200300296A (et) 2003-12-15
NO20032797L (no) 2003-08-19
ZA200304305B (en) 2004-09-02
SK7042003A3 (en) 2004-07-07
JP2005506281A (ja) 2005-03-03
HUP0303432A2 (hu) 2004-01-28
US6699852B2 (en) 2004-03-02
NO20032797D0 (no) 2003-06-19
EP1343791A2 (en) 2003-09-17
RU2003121304A (ru) 2005-01-27
MXPA03005438A (es) 2004-05-05
JP4231290B2 (ja) 2009-02-25
IL156354A0 (en) 2004-01-04

Similar Documents

Publication Publication Date Title
BG107865A (en) Substituted pyridoindoles as serotonin agonists and antagonists
BG107863A (en) Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
MXPA01012914A (es) Gama-carbolinas fundidas de heterociclo substituido.
ATE509929T1 (de) Substituierte tricyclische gamma-carbolineals serotonin-rezeptor-agonisten und antagonisten
IL156201A0 (en) Pyrazinoquioxaline derivatives and pharmaceutical compositions containing the same
GB0311349D0 (en) Therapeutic agents, compositions, preparations and uses